



## **ABLYNX IS GRANTED EXTENDED GMP CERTIFICATE FOR NEW GMP UNIT**

**GHENT, Belgium, 10 January 2012** - **Ablynx [Euronext Brussels: ABLX]** today announced that it has been granted an extended Certificate of Good Manufacturing Practice (GMP) from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium for its new GMP unit at its headquarters in Ghent, after having been inspected in November 2011.

Having received this accreditation, Ablynx's GMP unit will now perform release-testing on Drug Substance and Drug Product batches and independently perform all stability studies on these batches. The large scale GMP manufacturing of Nanobodies® will continue to be outsourced to contract manufacturing organisations (CMO).

Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "GMP certification of our laboratories in Ghent is a testament to Ablynx's commitment to consistently perform at a high standard in our internal and partnered development programmes. This is an important step forward as we continue to transform into a product-based company."

### **About Good Manufacturing Practice**

Good Manufacturing Practice (GMP) is that part of a Quality Management System which ensures that products are consistently produced and controlled to the quality standards appropriate to their intended use.

### **About the Federal Agency for Medicines and Health Products**

The [Federal Agency for Medicines and Health Products](#) (FAMHP) is the competent authority responsible for the quality, safety and efficacy of medicines and health products in Belgium.

### **About Ablynx**

[Ablynx](#) is a biopharmaceutical company engaged in the discovery and development of [Nanobodies](#)®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has over [25 programmes in the pipeline](#) and seven Nanobodies in clinical development. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis, and has had a collaboration with Pfizer. The Company is headquartered in Ghent, Belgium and currently employs over 290 people. More information can be found on [www.ablynx.com](http://www.ablynx.com).

### **For more information, please contact Ablynx:**

Dr Edwin Moses  
Chairman and CEO

Marieke Vermeersch  
Investor Relations Manager

t: +32 (0)9 262 00 07  
m: +44 (0)7771 954 193 /  
+32 (0)473 39 50 68  
e: [edwin.moses@ablynx.com](mailto:edwin.moses@ablynx.com)

t: +32 (0)9 262 00 82  
m: +32 (0)479 49 06 03  
e: [marieke.vermeersch@ablynx.com](mailto:marieke.vermeersch@ablynx.com)

*Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.*